AVP and autosomal dominant polycystic kidney disease: Thus, while copeptin is a promising biomarker for the prediction of outcome in patients with ADPKD without tolvaptan treatment, increased plasma copeptin in patients with ADPKD receiving tolvaptan should be interpreted with caution.